The fact that several 5-LOX and 12-LOX products are increased in OA and RA, albeit the participants underwent treatment, indicates that treatments targeting lipoxygenases (e.g., zileuton [92]) might be beneficial companion therapies to the current standard-of-care. This evidence concerns the gene ALOX15 and rheumatoid arthritis.